Log in
Products
Latest News
FAQ
Log in
|
Search
Search
Filters
Clear All
Study Phase
Early Phase 1
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
Phase 4
Not Applicable
Recruitment Status
Recruiting
Not yet recruiting
Active, not recruiting
Completed
Suspended
Terminated
Withdrawn
Study Type
Interventional
Observational
Expanded Access
Others
Eligibility Sex
All
Female
Male
Healthy Volunteers
All
Include
Exclude
Found
1
clinical trials
|
View Analysis
Sort by:
Newest First
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
Phase 2
Recruiting
Conditions
Multiple Myeloma
Interventions
Drug: Elrantamab
Device: clonoSEQ
Subscribe
First Posted Date
2024-07-03
Last Posted Date
2024-12-24
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
65
Registration Number
NCT06483100
Locations
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Subscribe
Prev
1
Next
© Copyright 2025. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy